Kv1.3 Inhibitors: Breakthrough Treatments for Autoimmune Disorders - What You Need to Know

Unibest Editor Note

In this comprehensive exploration of Kv1.3 channels and their therapeutic potential, we begin by examining the fundamental biology and diverse roles of these ion channels in cellular function. The article then delves into the significance of Kv1.3 in various neurological conditions, including ischemic stroke, Alzheimer's disease, epilepsy, and Parkinson's disease, highlighting its crucial role in neuroinflammation and disease progression.

Building on this scientific foundation, we introduce Unibest's groundbreaking Kv1.3 inhibitor assets, UB024 and UB029, which represent promising therapeutic solutions. UB024, a topical treatment for atopic dermatitis currently in Phase II trials, and UB029, an oral medication for inflammatory bowel disease in the IND phase, demonstrate the practical application of Kv1.3 targeting in treating inflammatory conditions.

For industry professionals and potential partners interested in these innovative assets, detailed information about licensing opportunities and NewCo possibilities is provided at the end of the article. Contact details are available for further discussions about these promising therapeutic candidates.

About Kv1.3 channel

The Kv1.3 channel, a classical Shaker-type potassium channel, holds a unique place in cellular biology. Initially discovered in T lymphocytes, it was the first K⁺ channel identified outside electrically excitable tissues, marking a significant milestone in our understanding of ion channel distribution. This channel is encoded by the intronless KCNA3 gene, located on chromosome 1p13.3 in humans, and comprises 575 amino acids. Kv1.3 channels exhibit remarkable versatility in their cellular localization, being found in the cell plasma membrane, inner mitochondrial membrane (mitoKv1.3), nuclear membrane, and the cis-Golgi apparatus membrane.

The functional roles of Kv1.3 channels are as diverse as their locations. In excitable cells, plasma membrane Kv1.3 channels are crucial for controlling resting potential and action potential. In non-excitable tissues, they play a vital role in regulating cell volume and proliferation. The mitochondrial variant, mitoKv1.3, serves a distinct purpose by regulating mitochondrial membrane potential, volume, and the production of reactive oxygen species (ROS). This multifaceted presence and functionality underscore the potential of Kv1.3 as a therapeutic target across various cellular processes and disease states.

Kv1.3 and Diseases

Recent studies have unveiled the widespread presence of Kv1.3 in other key immune cells, including macrophages, microglia, and effector memory T cells (TEM). This ubiquity underscores Kv1.3's significance in mediating immune and inflammatory responses. Of particular interest to the pharmaceutical industry is the channel's involvement in several autoimmune conditions, such as multiple sclerosis, rheumatoid arthritis, Type 1 diabetes, and asthma. In these disorders, Kv1.3 expression is notably elevated, providing both insight into the channel's role in autoimmune processes and a compelling rationale for developing Kv1.3 blockers as potential therapeutic agents.

The story of Kv1.3 doesn't end with autoimmune diseases, however. Cancer researchers have observed aberrant, predominantly high expression of Kv1.3 in various tumor types. This overexpression appears to confer a significant advantage to cancer cells, enhancing their ability to proliferate, migrate, and metastasize. As such, Kv1.3 has emerged as a promising target not only for autoimmune therapies but also for innovative cancer treatments.

ShK and Kv1.3 blocking polypeptides as potential therapeutic agents for neuroinflammatory diseases. ShK, Stichodactyla helianthus K⁺ channel blocking toxin (ShK) from the sea anemone S. helianthus. src. Wang, X. et al. Kv1.3 Channel as a Key Therapeutic Target for Neuroinflammatory Diseases: State of the Art and Beyond. Front. Neurosci. 13, 1393 (2020).

Multiple Sclerosis (MS)

Multiple Sclerosis is a chronic autoimmune disease that affects the central nervous system, causing damage to the myelin sheath that protects nerve fibers. This damage disrupts communication between the brain and the rest of the body, leading to a wide range of symptoms including vision problems, muscle weakness, and cognitive impairment. In the context of MS, Kv1.3 channels have emerged as a significant player in the disease's pathophysiology. Research has consistently demonstrated elevated expression levels of Kv1.3 in myelin-reactive T cells from the peripheral blood of MS patients compared to healthy controls. This overexpression is not merely coincidental but appears to be intimately linked to the disease process.

The heightened presence and activity of Kv1.3 channels in MS patients' T cells contribute to an overactive immune response, exacerbating the autoimmune attack on myelin. This understanding has led researchers to view Kv1.3 as a valuable therapeutic target for immunosuppression in MS.

Ischemic Stroke

Ischemic stroke is a severe cardiovascular event characterized by the sudden interruption of blood flow to a part of the brain, typically due to a blood clot. This lack of blood supply leads to oxygen deprivation in the affected area, causing rapid cell death and potential long-term neurological deficits. While the initial damage occurs quickly, secondary inflammation can significantly expand the infarct area, worsening the outcome for patients.

The pathophysiological role of Kv1.3 in ischemic stroke can be understood through several key mechanisms:

• - Microglial and Macrophage Activation: Kv1.3 modulates calcium (Ca²⁺) signaling in these cells, which is essential for their activation and transition to a pro-inflammatory state.

• - Oxidative Burst: The channel contributes to the production of reactive oxygen species (ROS), a hallmark of inflammation that can cause further tissue damage.

• - Cytokine Production: Kv1.3 activity influences the release of pro-inflammatory cytokines, amplifying the inflammatory response in the ischemic area.

• - Neuronal Killing: Activated microglia and macrophages can directly contribute to neuronal death, partly through mechanisms involving Kv1.3.

• - M1-like Pro-inflammatory Activation: Kv1.3 is required for microglia and macrophages to adopt an M1-like pro-inflammatory phenotype in vivo, which is associated with tissue damage.

Alzheimer's Disease (AD)

AD is a devastating neurodegenerative disorder that affects millions worldwide, characterized by progressive memory loss and cognitive decline. Microglia, the brain's resident immune cells, play a crucial role in AD by mediating neuroinflammation. The Kv1.3 channels act as key regulators of microglial function. Studies have shown that Kv1.3 is instrumental in immune cell activation by modulating calcium signaling. In AD models, researchers have observed high expression of Kv1.3 in pro-inflammatory microglia.

Notably, the expression of Kv1.3 is increased in the brains of AD patients, with this elevation specifically localized to microglial cells. This finding suggests a potential link between Kv1.3 overexpression and the chronic inflammation characteristic of AD.

Epilepsy

Epilepsy is a neurological disorder characterized by recurrent seizures. At the heart of this condition lies an imbalance in neuronal excitability, and recent research has highlighted the crucial role of potassium channels, particularly the Kv1.3 channel, in this process. Potassium channels are fundamental in maintaining the resting membrane potential of neurons and regulating their excitability. When these channels malfunction, it can lead to various neurological disorders, including epilepsy, neuropathic pain, and ataxia. Within the Kv channel family, the Kv1 subfamily has been identified as particularly significant in determining susceptibility to epilepsy in the brain.

Interestingly, many symptoms of neuronal hyperexcitability, including epileptic seizures, have been linked to mutations or downregulation of Kv1 channels. Recent studies have shed light on the specific role of the Kv1.3 channel in epilepsy. Researchers have found that pentylenetetrazol, a known convulsant agent, significantly reduces Kv1.3 currents. This finding suggests a potential association between Kv1.3 channel function and epileptogenesis - the process by which a normal brain develops epilepsy.

Parkinson's Disease (PD)

PD is a progressive neurodegenerative disorder that primarily affects movement, balance, and coordination.Recent research has shed light on the intriguing connection between Kv1.3 channels and PD. In the striatum, a brain region crucial for motor control, Kv1.3-mediated currents are significantly reduced in PD patients. This reduction leads to decreased inhibition of cholinergic interneuron excitability, potentially contributing to the motor symptoms characteristic of the disease.

Moreover, scientists have observed that microglia, the brain's immune cells, become activated in the early stages of PD and remain active throughout the disease progression. This activation is marked by an upregulation of potassium channels, with Kv1.3 and Kv1.5 channels playing prominent roles. Intriguingly, as microglial cells proliferate, Kv1.3 currents become the predominant force, suggesting a critical role for these channels in sustained microglial activation and the ongoing inflammatory processes in PD.

Targeting Kv1.3

Designing a drug that effectively targets the Kv1.3 channel has proven to be a complex and challenging endeavor, despite its promising potential as a therapeutic target for various diseases. To date, no Kv1.3 inhibitors have successfully reached the market, leaving this target largely underexploited. Let's explore some of the key obstacles researchers face in developing effective Kv1.3 inhibitors.

One of the primary challenges lies in the high degree of homology within the Kv channel family. This structural similarity makes it difficult to design a drug that is both selective for Kv1.3 and safe, as unintended interactions with other Kv channels could lead to unwanted side effects.

Another significant hurdle is the lack of a crystal structure for the Kv1.3 channel or a small-molecule inhibitor in complex with any of the Kv1.x isoforms. Such structural information would provide invaluable insights into the binding interactions, potentially accelerating the development of more potent and selective inhibitors. Without this crucial data, researchers are somewhat hindered in their efforts to optimize drug design.

Furthermore, creating inhibitors with the appropriate physicochemical properties presents its own set of challenges. These properties are essential for effective drug administration and the ability to penetrate biological barriers, allowing the inhibitor to reach Kv1.3 channels in both the plasma membrane and the inner mitochondrial membrane.

Unibest's Kv1.3 asset - UB024 & UB029

Unibest is proud to introduce two innovative small molecule assets, UB024 and UB029, which are now available for global licensing and NewCo opportunities. These Kv1.3 inhibitor assets represent a significant advancement in the field of autoimmune and inflammatory disorders.

The Science Behind UB024 and UB029

Both assets utilize a novel mechanism of action as selective ion channel inhibitors targeting Kv1.3. This unique approach effectively down-regulates the activity of effector memory T cells, thereby mitigating pathological autoimmune responses. This targeted action positions UB024 and UB029 as promising candidates for treating various inflammatory conditions.

UB024: A Breakthrough in Atopic Dermatitis Treatment

UB024, formulated as a topical ointment, is currently undergoing Phase II clinical trials for atopic dermatitis. Preclinical studies in rat models have shown remarkable results:

• - Significant, dose-dependent reduction in ear inflammation

• - No hypertrophy of the spinous layer at high concentrations

• - Decreased inflammatory cell infiltration in the dermis

The successfully completed Phase I trial demonstrated an excellent safety and tolerability profile:

• - Randomized, double-blind, placebo-controlled study

• - No dose-limiting toxicities or local intolerance observed

• - No serious adverse events reported

Given these promising results, we anticipate UB024 becoming a first-line treatment for mild to moderate atopic dermatitis, particularly benefiting high-incidence populations such as children and infants.

UB029: Oral Therapy for Inflammatory Bowel Disease and Beyond

UB029, designed for oral administration, is currently in the IND phase for inflammatory bowel disease (IBD). Preclinical studies have yielded impressive results:

• - Significant reduction in body weight loss and Disease Activity Index (DAI) scores in IBD rat models

• - Superior therapeutic effects compared to the established drug Mesalamine

• - Positive outcomes in additional animal models, including colitis, atopic dermatitis, and psoriasis

These broad-ranging results suggest UB029 may have applications across multiple inflammatory conditions, opening up exciting possibilities for clinical development.

Explore Licensing and NewCo Opportunities

The potential of UB024 and UB029 as Kv1.3 inhibitor assets represents a significant opportunity in the treatment of autoimmune and inflammatory disorders. We invite interested parties to contact us at bd@unibestcn.com to discuss licensing and NewCo opportunities for these promising assets.

References